Abstract
Efficacy and safety results from a pivotal phase 3 trial of DTX401, an AAV8-mediated liver-directed gene therapy, in individuals with glycogen storage disease type Ia (GSDIa)
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have